143225-31-4

Basic information

• Product Name: (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol
• Synonyms: (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol
• CAS NO: 143225-31-4
• Molecular Weight: 336.475
• Mol File: 143225-31-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol(143225-31-4)
• EPA Substance Registry System: (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol(143225-31-4)

Safety Data

• Hazardous Substances Data: 143225-31-4(Hazardous Substances Data)

Usage

Description

(2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol is a chiral amino alcohol with a complex and specific structure. It contains a tert-butyloxycarbonyl (Boc) protected amino group, an isobutylamino group, and a phenyl group. (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol has two stereocenters, with the (2S,3S) configuration indicating the stereochemistry of the molecule.

Uses

Used in Organic Synthesis:
(2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol is used as a building block for the synthesis of complex organic molecules. Its unique structure and stereochemistry make it a valuable component in the creation of various organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (2S,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1-(isobutylamino)-4-phenylbutan-2-ol is used as a building block for the synthesis of pharmaceutical compounds. Its specific structure and stereochemistry allow for the development of new drugs with potential therapeutic applications.

Upstream product

• 78-81-9 isobutylamine 
• 220871-52-3 1(R,S)-<1'-(S)-<(tert-butyloxycarbonyl)amino>-2-phenylethyl>oxirane 
• 103127-56-6 [S-(R*,R*)]-(1-oxiranyl-2-phenylethyl)-carbamic acid 1,1-dimethylethyl ester 
• 103127-52-2 ((S)-1-benzylallyl)carbamic acid tert-butyl ester 
• 162541-34-6 ((1S,2S)-3-Amino-1-benzyl-2-hydroxy-propyl)-carbamic acid tert-butyl ester 
• 174302-74-0 (2S,3S)-N-tert-butyloxycarbonyl-2-amino-3-hydroxy-1-phenyl-4-nitrobutane 
• 72155-45-4 Boc-L-phenylalaninal 
• 98760-08-8 (2R,3S)-3-[N-(tert-butyloxycarbonyl)amino]-1,2-epoxy-4-phenylbutane 

Downstream Products

• 1055033-36-7 [(1S,2S)-1-Benzyl-2-hydroxy-3-(1-isobutyl-3-methyl-ureido)-propyl]-carbamic acid tert-butyl ester 
• 1054616-60-2 [(1S,2S)-1-Benzyl-3-(3-butyl-1-isobutyl-ureido)-2-hydroxy-propyl]-carbamic acid tert-butyl ester 
• 866227-35-2 (5S,6S)-3-aza-6-{[(tert-butyloxycarbonyl)-L-valinyl]amino}-3-isobutyl-5-hydroxy-7-phenylheptanoyl amide 
• 192800-79-6 4-amino-N-((2S,3S)-2-hydroxy-4-phenyl-3-amino-butyl)-N-isobutyl-benzenesulfonamide 
• 1053694-18-0 1-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-1-isobutyl-3-methyl-urea 
• 686706-81-0 1-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-3-tert-butyl-1-isobutyl-urea 
• 1053634-50-6 1-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-3-butyl-1-isobutyl-urea 
• 143616-96-0 {(S)-1-[(1S,2S)-1-Benzyl-3-(3-tert-butyl-1-isobutyl-ureido)-2-hydroxy-propylcarbamoyl]-2-carbamoyl-ethyl}-carbamic acid benzyl ester 
• 143224-34-4 (S)-N¹-[(1S,2S)-1-Benzyl-3-(3-tert-butyl-1-isobutyl-ureido)-2-hydroxy-propyl]-2-[(quinoline-2-carbonyl)-amino]-succinamide 
• 1393747-10-8 C₂₆H₃₄N₄O₃ 

Relevant articles and documents

Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors

A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl)amino)-N-isobutylbenzo[d]oxazole- 6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers.

Ethylaziridine derivatives and their preparation methods

This invention is related to new ethylaziridine derivatives of formula (I) and their preparation. The compounds are useful synthetic intermediates for the synthesis of HIV protease inhibitors and oligopeptide mimetics.

Discovery of a Novel Class of Potent HIV-1 Protease Inhibitors Containing the (R)-(Hydroxyethyl)urea Isostere

-